lung squamous cell carcinoma (Cancer)

Search with Google Search with Bing
Information
Disease name
lung squamous cell carcinoma
Disease ID
DOID:3907
Description
"A non-small cell lung carcinoma that has_material_basis_in the squamous cell." [url:http\://cancergenome.nih.gov/cancersselected/lungsquamouscell, url:http\://en.wikipedia.org/wiki/Squamous-cell_carcinoma, url:http\://en.wikipedia.org/wiki/Squamous_cell_carcinoma_of_the_lung, url:http\://www.cancer.gov/dictionary?CdrID=46595]
Disease area statistics
Chromosome band
Gene symbol Chromosome Start Stop The number of variant
TP53 17 7,668,421 7,687,490 6
KEAP1 19 10,486,126 10,502,896 6
NOTCH1 9 136,494,433 136,546,048 4
FAT1 4 186,587,794 186,723,856 4
JAK3 19 17,824,782 17,847,982 4
SOX2-OT 3 180,989,779 181,742,884 4
SOX2 3 181,711,925 181,714,436 4
H3C14 1 149,840,687 149,841,208 4
RBL1 20 36,996,349 37,095,997 2
KDM5A 12 280,057 389,320 2
Annotation
Genes Mutation Description Source Links
NCT ID Status Phase Summary Start date Completion date
NCT04152018 Active, not recruiting Phase 1 Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. November 13, 2019 August 30, 2024
NCT01386385 Active, not recruiting Phase 1/Phase 2 Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery June 20, 2011 December 31, 2024
NCT00334815 Active, not recruiting Phase 2 Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery June 15, 2006 February 22, 2025
NCT01807546 Completed Phase 2 Oral Rigosertib for Squamous Cell Carcinoma March 2013 April 2016
NCT06436040 Recruiting Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma January 24, 2024 May 16, 2025
NCT04802876 Recruiting Phase 2 Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors April 12, 2021 March 31, 2027
NCT05778253 Recruiting The Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC March 23, 2023 September 23, 2029
NCT05782764 Recruiting Phase 4 A Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom June 1, 2023 May 30, 2025
NCT06255197 Recruiting Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers November 4, 2019 December 31, 2031
NCT05010330 Unknown status Identify Prognostic Biomarkers of Lung Cancer July 1, 2020 September 30, 2021
NCT05024266 Unknown status Phase 2 Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma August 1, 2021 August 31, 2023
NCT04132102 Unknown status Phase 4 To Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation November 27, 2018 August 31, 2021
NCT03725423 Unknown status Phase 4 Apatinib for Advanced Lung Squmamous Carcinoma October 2018 June 2019
NCT02876978 Unknown status Phase 1 Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma March 2016 April 2019
NCT04267913 Withdrawn Phase 2 Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial) September 5, 2020 October 31, 2026
Disase is a (Disease Ontology)
DOID:3908
Cross Reference ID (Disease Ontology)
NCI:C3493
Cross Reference ID (Disease Ontology)
SNOMEDCT_US_2023_03_01:254634000
Cross Reference ID (Disease Ontology)
UMLS_CUI:C0149782
Exact Synonym (Disease Ontology)
Epidermoid cell carcinoma of the lung
Disase Synonym (Disease Ontology)
squamous cell carcinoma of lung